Chatzilygeroudi, Theodora
Chondrou, Vasiliki
Boers, Ruben
Siamoglou, Stavroula
Athanasopoulou, Katerina
Verigou, Evgenia
Gribnau, Joost
Alexis, Spyridon
Labropoulou, Vassiliki
Kourakli, Alexandra
Patrinos, George P.
Sgourou, Argyro
Symeonidis, Argiris
Funding for this research was provided by:
Special Account for Research Funding (ELKE) of the University of Patras (project identification code 80305)
Article History
Received: 13 March 2024
Accepted: 27 May 2024
First Online: 15 June 2024
Declarations
:
: The study was approved by the University General Hospital of Patras Ethics Committee (approval number 33807/24.12.2020). All patients provided their written informed consent according to the Declaration of Helsinki, being informed about both clinical and translational investigations.
: Not applicable.
: A.Sy. has conducted clinical trials and has received research funding through the University of Patras, honoraria and/or travel expenses by Abbvie, Agios, Amgen, Astra-Zeneca, BMS, Incyte/Genesis, Gilead, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, Sobi and Takeda. A.K. has conducted clinical trials and has received honoraria and/or travel expenses by Abbvie, Agios, Demo/ApoPharma, BMS, Incyte/Genesis, Janssen, Novartis, Pfizer and Sobi. VL has received honoraria and/or travel expenses by Abbvie, Amgen, Demo/ApoPharma, GSK, Incyte/Genesis, Janssen, Sanofi and Win-Medica. EV has received honoraria and/or travel expenses by Abbvie, Gilead and Pfizer. R.B. and J.G. are shareholders in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging. The remaining co-authors have nothing to disclose.